Company profile
RC Harwell | RC Harwell
Neovac Ltd is a UK company with status active founded in 2021 based in South East England.
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
CS01 | Transaction MzUxNTIwNjcwMGFkaXF6a2N4
Published 10 Apr 2026 08:58
Last confirmation statement made up date
AP01 | Transaction MzUxMjUzNTA1MGFkaXF6a2N4
Published 25 Mar 2026 13:42
Last accounts made up date
AA | Transaction MzQ0MjQ5MTQxNmFkaXF6a2N4
Published 08 Nov 2024 03:48
AA01 | Transaction MzQ0MjQ5MDc2MmFkaXF6a2N4
Published 08 Nov 2024 03:41
AD01 | Transaction MzQ0MTg3OTY1NmFkaXF6a2N4
Published 04 Nov 2024 11:33
RESOLUTIONS | Transaction WURDODdXRTlhZGlxemtjeA | Paper/PDF filed
Published 01 Oct 2024 06:28
Company registered at Companies House
1 Apr 2025 to 31 Mar 2027
RNA therapeutics have emerged as a revolutionary approach to treating diseases, offering a powerful platform for delivering therapeutic RNA molecules encapsulated in lipid nanoparticles (LNPs). These LNPs protect the RNA in the bloodstream, enhancing its stability and ensuring it reaches its target cells. The recent success of mRNA-based COVID-19 vaccines...
1 Oct 2023 to 30 Sep 2025
The purpose of this project is to develop a mRNA vaccine against the Plague that is easy and suitable for distribution and use in lower- and middle-income countries (LMICs). Plague is a deadly disease caused by bacteria called _Yersinia pestis_(_Y. pestis_). Plague has caused millions of deaths throughout recorded history, most notoriously in the 1300s th...
1 May 2023 to 30 Apr 2027
Malaria killed about 640 thousand people in 2020, largely young children in Africa. Rapid recent progress has led to two anti-sporozoite vaccine developers planning WHO prequalification applications in 2022. These include the new high efficacy R21/Matrix-M vaccine, to be supplied at the required large scale, and led by partners in this consortium. In para...
